Cervarix, Gardasil Approved for New Indications

GlaxoSmithKline’s human papillomavirus vaccine Cervarix has received FDA approval for use in girls and young women age 10–25, while Merck’s Gardasil has won a new indication, extending its use to boys and men age 9–26. GSK expects to make the vaccine commercially available in the U.S. this year, providing competition for Gardasil, (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) which had global sales of $1.4 billion worldwide last year, according to an SEC filing.
Washington Drug Letter